A5034541004- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Pancreatic and Hepatic Oncology Research
- Multiple and Secondary Primary Cancers
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Inflammatory Biomarkers in Disease Prognosis
- Ovarian cancer diagnosis and treatment
- COVID-19 and healthcare impacts
- CAR-T cell therapy research
- Radiopharmaceutical Chemistry and Applications
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Breast Cancer Treatment Studies
- Tryptophan and brain disorders
Juravinski Cancer Centre
2018-2025
McMaster University
2018-2025
McMaster University Medical Centre
2018-2024
University Health Network
2024
Sinai Hospital
2024
University of Toronto
2024
Hamilton Health Sciences
2021-2023
Juravinski Hospital
2022
Dana-Farber Cancer Institute
2017-2020
Beth Israel Deaconess Medical Center
2020
<h3>Background</h3> An elevated Neutrophil-to-lymphocyte ratio (NLR) is associated with worse outcomes in several malignancies. However, its role contemporary immune checkpoint blockade (ICB) unknown. We investigated the utility of NLR metastatic renal cell carcinoma (mRCC) patients treated PD-1/PD-L1 ICB. <h3>Methods</h3> examined at baseline and 6 (±2) weeks later 142 between 2009 2017 Dana-Farber Cancer Institute (Boston, USA). Landmark analysis 6 weeks was conducted to explore...
Abstract Despite remarkable success of immune checkpoint inhibitors, the majority cancer patients have yet to receive durable benefits. Here, in order investigate metabolic alterations response blockade, we comprehensively profile serum metabolites advanced melanoma and renal cell carcinoma treated with nivolumab, an antibody against programmed death protein 1 (PD1). We identify kynurenine/tryptophan ratio increases as adaptive resistance mechanism associated worse overall survival. This...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
The combination of immuno-oncology (IO) agents ipilimumab and nivolumab (IPI-NIVO) vascular endothelial growth factor targeted therapies (VEGF-TT) combined with IO (IO-VEGF) are current standard care first-line treatments for metastatic renal cell carcinoma (mRCC).
Abstract Programmed death 1 (PD-1) and PD ligand (PD-L1) inhibitors have shown activity in metastatic clear cell renal carcinoma (ccRCC). Data on the of these agents patients with non–clear RCC (nccRCC) or sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we explored efficacy PD-1/PD-L1 nccRCC differentiation. Baseline follow-up demographic, clinical, treatment, radiographic data were collected. The primary endpoint was objective response rate. Secondary...
Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population clinical trials. We analyzed data for patients or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total 389/4799 (8.1%) had on initiation systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated longer median overall survival (OS; 32.7 mo, 95% confidence...
Abstract The current standard of care for treatment metastatic renal cell carcinoma (mRCC) patients is PD-1/PD-L1 inhibitors until progression or toxicity. Here, we characterize the clinical outcomes 19 mRCC who experienced an initial response (any degree tumor shrinkage), but after immune-related adverse events (irAE) discontinued all systemic therapy. Clinical baseline characteristics, outcomes, and survival data were collected. primary endpoint was time to from date cessation (TTP). Most...
Abstract Urologic cancers include of the bladder, kidney, prostate, and testes, with common molecular features spanning different types. Here, we show that 1954 urologic can be classified into nine major genomic subtypes, on basis multidimensional comprehensive characterization (including DNA methylation copy number, RNA protein expression). Tissue dominant effects are first removed computationally in order to define these which reveal processes—reflecting part tumor microenvironmental...
Abstract Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness dosing patterns of cabozantinib are not well characterized. Methods Patients with mRCC treated between 2011 2019 were identified stratified using International Database Consortium (IMDC) risk groups. First‐ (1L), second‐ (2L), third‐ (3L), fourth‐line (4L) overall response rate (ORR), time to treatment failure (TTF), survival (OS)...
<h3>Background</h3> Monoclonal antibodies targeting the PD-1/PD-L1 axis have gained increasing attention across many solid tumors and hematologic malignancies due to their efficacy favorable toxicity profile. With more than 1 agent now FDA-approved in a wide variety of tumor types, with others clinical trials, it is becoming common that patients present clinic for potential treatment second inhibitor. <h3>Case presentation</h3> In this report, we two renal cell carcinoma one melanoma who...
The genomic landscape of primary clear cell renal carcinoma (ccRCC) has been well described. However, little is known about cohort alterations (GA) in ccRCC metastases, or how it compares to tumours aggregate. metastases may have biological, clinical, and therapeutic implications.We collected targeted next-generation sequencing mutation calls from two independent cohorts described the GA descriptively compared tumours.The 1 (n = 578) consisted 349 229 metastases. Overall, most common...
An elevated body mass index (BMI; calculated as weight in kilograms divided by height meters squared) has been associated with an increased risk of renal cell carcinoma (RCC). 1 Previously, higher BMI was shown to be a positive prognostic factor for patients metastatic clear RCC (mRCC) who were treated during the vascular endothelial growth (VEGF)-targeted therapy era. 2 However, treatment landscape shifted include immune checkpoint inhibitors (ICIs) most patients.We investigated t h i s o b...
To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib.
In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated a robust objective response rate of 71%. Here we report tumor responses for L P arm CLEAR, median follow-up ∼4 yr at final prespecified overall survival (OS) analysis. Tumor were assessed by independent review using Response Evaluation Criteria Solid Tumors v1.1. Patients...